Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2000 March; 1(1): 50–59.
Published online 2015 February 19. doi:  10.1208/pt010106
PMCID: PMC2784833

Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide


Pramlintide is a 37-amino acid peptide that is being evaluated as a drug candidate for treating people with type 1 and insulin-using type 2 diabetes. Two high-performance liquid chromatography (HPLC) methods were developed for quantitating related substance impurities in pramlintide drug substance as well as degradation products of pramlintide formulated for parenteral administration. The methods differ with respect to separation mode and therefore provide orthogonal information concerning related substances and degradation products. One method uses a reverse phase (RP) separation mode, and the other involves a strong cation exchange (SCX) separation. Method performance testing showed that the RP- and SCX-HPLC methods both afford a high degree of selectivity, accuracy, precision, and sensitivity. The limit of quantitation for determining spiked authentic samples of degradation products was shown to be approximately 0.1% (relative to intact pramlintide) for both methods. Relative retention times for known pramlintide degradation products were determined for both the RP- and SCX-HPLC methods, demonstrating the selectivities of the 2 methods as well as the orthogonality of the information. The methods were also shown to be diastereospecific with respect to separating pramlintide from authentic samples of D-isomers at Ala5, Ala8, Ala5-Ala8, and Leu12. The methods did not resolve pramlintide, however, from diastereomers with D-isomers near the C- and N-termini, namely Lys1,Cys2, and Tyr37.

Keywords: Pramlintide, Peptide Analysis, RP-HPLC, SCX-HPLC, Orthogonal Separation, Diastereoselectivity

Full Text

The Full Text of this article is available as a PDF (309K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325–331. [PubMed]
2. Young AA. Amylin regulation of fuel metabolism. J Cellular Biochem. 1994;55(Supp):12–18. doi: 10.1002/jcb.240550003. [PubMed] [Cross Ref]
3. Amiel S. Amylin and diabetes. Lancet. 1993;341:1249–1250. doi: 10.1016/0140-6736(93)91153-D. [PubMed] [Cross Ref]
4. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45(Suppl 2):235A–235A.
5. Ahem TJ, Manning MC, editors. Stability of Protein Pharmaceuticals. Part A. Chemical and Physical Pathways of Protein Degradation. New York, NY: Plenum Press; 1992.
6. Manning MC, Patel K, Borchardt RT. Stability of protein pharmaceuticals. Pharm Res. 1989;6:903–917. doi: 10.1023/A:1015929109894. [PubMed] [Cross Ref]
7. Patel K, Borchardt RT. Chemical pathways of degradation III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res. 1990;7:787–793. doi: 10.1023/A:1015999012852. [PubMed] [Cross Ref]
8. Capasso S, Mazzarella L, Zagari A. Deamidation via cyclic imide of asparaginyl peptides: dependence on salts, buffers, and organic solvents. Peptide Res. 1991;4:234–241. [PubMed]
9. Robinson AB, Scotchler JW, McKerrow JM. Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides. J Am Chem Soc. 1973;85:8156–8159. doi: 10.1021/ja00805a032. [PubMed] [Cross Ref]
10. Hekman C, Demond W, Dixit T, et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug product. Pharm Res. 1998;15:650–659. doi: 10.1023/A:1011934829263. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists